Q-omics provides the consensus-scored CHST8 profile across patient tissues and cancer cell-line models. CHST8 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CHST8 is differentially expressed in 9, with the highest sampling consensus in COAD. Additionally, CHST8 RNA expression shows 12,268 significant gene co-expression associations, with the highest sampling consensus in STAD. Together, these results highlight KIRC, COAD, and STAD as cancer lineages where CHST8 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CHST8 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CHST8 survival associations across molecular data types. CHST8 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CHST8 RNA expression–survival associations across cancer types. High CHST8 expression shows unfavorable associations in KIRC, BLCA, UVM and OV, but favorable associations in LUAD and UCS. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for CHST8 RNA expression.
This table summarizes CHST8 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for CHST8. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CHST8 shows lower tumor expression in COAD, THCA, UCEC and HNSC and higher tumor expression in BRCA and LIHC. The COAD box plot shows higher CHST8 RNA expression in normal versus tumor tissue (log2 FC = −0.340, t-test p < 0.001).
This table shows molecular features associated with CHST8 in patient tissues and cancer cell lines. In patient samples, CHST8 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, CHST8 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in CNS and SOFT_TISSUE.
